Prexton CEO on future for novel Parkinson’s therapy

April 11, 2017 Christoph Graener

As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company’s technology and its future. Prexton raised EUR 29 million via a series B financing earlier this year to progress foliglurax, a metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM), into Phase II trials. A European Phase II trial is expected to enroll its first patient in June and will be completed by the end of 2018. A US trial is also planned. After Phase II, Conquet hopes the company will be able to license the compound to a big pharma for Phase III development.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: François Conquet – CEO, Prexton Therapeutics

Previous Article
Partnerships are key for rare disease drug discovery and development

An in-depth interview with Wendy White, Board Chairman of Global Genes, the leading global rare disease pat...

Next Article
Biomunex CSO defines lead compounds, early R&D plans

Eugene Zhukovsky, CSO at Biomunex, talks about the company's clinical development strategy of using monospe...